Matthew Meyerson

307.6k citations

287 papers · 58.9k indexed · 28 hit papers · h-index 100

Molecular Biology top 0.02%
Oncology top 0.01%
Pulmonary and Respiratory Medicine top 0.01%
Cancer Research top 0.01%
Genetics top 0.1%

Co-authors: Gad Getz Michael J. Eck Pasi A. Jänne Heidi Greulich Bruce E. Johnson Stacey Gabriel Titus J. Boggon William R. Sellers
Topics: Cancer Genomics and Diagnostics (68 papers)Lung Cancer Treatments and Mutations (64 papers)RNA modifications and cancer (40 papers)
Cited by: Cancer Research Oncology Pulmonary and Respiratory Medicine
Journals: Nature Science New England Journal of Medicine
Partner nations: United States Germany Canada

In The Last Decade

Matthew Meyerson

277 papers receiving 57.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

2004 7.5k citations J. Guillermo Paez, Pasi A. Jänne et al. Science profile →
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

2005 3.2k citations Susumu Kobayashi, Titus J. Boggon et al. profile →
Discovery and saturation analysis of cancer genes across 21 tumour types

2014 2.1k citations Levi A. Garraway, Todd R. Golub et al. profile →
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers

2011 2.0k citations Matthew Meyerson, Rameen Beroukhim et al. profile →
Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses

2001 2.0k citations William G. Richards, Stefano Monti et al. Proceedings of the National Academy of Sciences profile →
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment

2013 1.9k citations Matthew Meyerson et al. profile →
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

2008 1.6k citations Cai‐Hong Yun, Kristen E. Mengwasser et al. Proceedings of the National Academy of Sciences profile →
hEST2, the Putative Human Telomerase Catalytic Subunit Gene, Is Up-Regulated in Tumor Cells and during Immortalization

1997 1.5k citations Matthew Meyerson et al. profile →
Genomic analysis identifies association of Fusobacterium with colorectal carcinoma

2011 1.4k citations Adam J. Bass, Matthew Meyerson et al. profile →
Pan-cancer patterns of somatic copy number alteration

2013 1.2k citations Andrew D. Cherniack, Stacey Gabriel et al. profile →
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

2008 1.2k citations Takeshi Shimamura, Geoffrey I. Shapiro et al. profile →
Absolute quantification of somatic DNA alterations in human cancer

2012 1.1k citations Barbara A. Weir, Rameen Beroukhim et al. profile →
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

2005 1.1k citations Levi A. Garraway, Mark A. Rubin et al. profile →
Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

2007 904 citations Cai‐Hong Yun, Titus J. Boggon et al. profile →
Inhibition of telomerase limits the growth of human cancer cells

1999 862 citations William C. Hahn, Matthew Meyerson et al. profile →
Advances in understanding cancer genomes through second-generation sequencing

2010 798 citations Matthew Meyerson, Stacey Gabriel et al. profile →
A family of human cdc2-related protein kinases.

1992 791 citations Matthew Meyerson et al. profile →
Chromothripsis from DNA damage in micronuclei

2015 787 citations Joshua M. Francis, Matthew Meyerson et al. profile →
Recurrent BRAF mutations in Langerhans cell histiocytosis

2010 742 citations Gayane Badalian‐Very, Jo‐Anne Vergilio et al. Blood profile →
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling

2011 732 citations Nikhil Wagle, Michael F. Berger et al. Journal of Clinical Oncology profile →
Commensal Microbiota Promote Lung Cancer Development via γδ T Cells

2019 711 citations Matthew Meyerson et al. profile →
Identification of G1 kinase activity for cdk6, a novel cyclin D partner.

1994 705 citations Matthew Meyerson et al. profile →
PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib

2007 598 citations Jeffrey A. Engelman, Takeshi Shimamura et al. Cancer Research profile →
Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening

2019 536 citations Alison M. Taylor, Matthew Meyerson et al. profile →
Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants

2005 536 citations Heidi Greulich, Pasi A. Jänne et al. profile →
Menin Associates with a Trithorax Family Histone Methyltransferase Complex and with the Hoxc8 Locus

2004 504 citations Jeffrey C. Lee, Matthew Meyerson et al. profile →
Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors

2013 422 citations Juliann Chmielecki, David A. Frank et al. profile →
Patterns of Gene Expression and Copy-Number Alterations in von-Hippel Lindau Disease-Associated and Sporadic Clear Cell Carcinoma of the Kidney

2009 310 citations Rameen Beroukhim, Mark A. Rubin et al. Cancer Research profile →

Peers

Countries citing papers authored by Matthew Meyerson

Since Specialization

Citations

This map shows the geographic impact of Matthew Meyerson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Meyerson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Meyerson more than expected).

Fields of papers citing papers by Matthew Meyerson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Meyerson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Meyerson. The network helps show where Matthew Meyerson may publish in the future.

Co-authorship network of co-authors of Matthew Meyerson

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Meyerson. A scholar is included among the top collaborators of Matthew Meyerson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Meyerson. Matthew Meyerson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Functional Genomic Analysis of CDK4 and CDK6 Gene Dependency across Human Cancer Cell Lines 2022 ·Cancer Research ·Zhouwei Zhang,Lior Golomb,Matthew Meyerson	26
2	Genomic Profiling of Prostate Cancers from Men with African and European Ancestry 2020 ·Clinical Cancer Research ·Yusuke Koga,Hanbing Song,Zachary R. Chalmers,Justin Y. Newberg,Eejung Kim,Jian Carrot‐Zhang,(unknown),Paz Polak,Sarki A. Abdulkadir,Elad Ziv,Matthew Meyerson,Garrett M. Frampton,Joshua D. Campbell,Franklin W. Huang	58
3	RAS–MAPK Reactivation Facilitates Acquired Resistance in FGFR1 -Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR–MEK Blockade 2018 ·Molecular Cancer Therapeutics ·Bruno Bockorny,Maria Rusan,Wankun Chen,Rachel G. Liao,Yvonne Li,Federica Piccioni,Jun Wang,Li Tan,Aaron R. Thorner,Tianxia Li,Y. Zhang,Changhong Miao,Therese Ovesen,Geoffrey I. Shapiro,David J. Kwiatkowski,Nathanael S. Gray,Matthew Meyerson,Peter S. Hammerman,Adam J. Bass	43
4	Somatic Superenhancer Duplications and Hotspot Mutations Lead to Oncogenic Activation of the KLF5 Transcription Factor 2017 ·Cancer Discovery ·Xiaoyang Zhang,Peter S. Choi,Joshua M. Francis,Galen F. Gao,Joshua D. Campbell,Aruna Ramachandran,Yoichiro Mitsuishi,Gavin Ha,Juliann Shih,Francisca Vázquez,Aviad Tsherniak,Alison M. Taylor,Jin Zhou,Zhong Wu,Ashton C. Berger,Marios Giannakis,William C. Hahn,Andrew D. Cherniack,Matthew Meyerson	85
5	MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma 2017 ·Cancer Research ·Xinyuan Lu,Nir Peled,John J. Greer,Wei Wu,Peter S. Choi,Alice H. Berger,Sergio Wong,Kuang‐Yu Jen,Youngho Seo,Byron Hann,Angela N. Brooks,Matthew Meyerson,Eric A. Collisson	49
6	Identification of an “Exceptional Responder” Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy 2015 ·Molecular Cancer Research ·Hugh Gannon,Nathan O. Kaplan,Aviad Tsherniak,Francisca Vázquez,Barbara A. Weir,William C. Hahn,Matthew Meyerson	19
7	Whole-Exome Sequencing Reveals Frequent Genetic Alterations in BAP1 , NF2 , CDKN2A , and CUL1 in Malignant Pleural Mesothelioma 2014 ·Cancer Research ·Guangwu Guo,Juliann Chmielecki,Chandra Goparaju,Adriana Heguy,Igor Dolgalev,Michele Carbone,Sara Seepo,Matthew Meyerson,Harvey I. Pass	229
8	Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC 2014 ·Cancer Research ·Jeremy H. Tchaicha,Esra A. Akbay,Abigail Altabef,Oliver R. Mikse,Eiki Kikuchi,Kevin Rhee,Rachel G. Liao,Roderick T. Bronson,Lynette M. Sholl,Matthew Meyerson,Peter S. Hammerman,Kwok‐Kin Wong	30
9	Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer 2013 ·Cancer Research ·Mohamed E. Abazeed,Drew Adams,Kristen E. Hurov,Pablo Tamayo,Chad J. Creighton,Dmitriy Sonkin,Andrew O. Giacomelli,(unknown),(unknown),Kwok‐Kin Wong,Jill P. Mesirov,Jay S. Loeffler,Stuart L. Schreiber,Peter S. Hammerman,Matthew Meyerson	90
10	Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non–Small Cell Lung Cancer 2012 ·Clinical Cancer Research ·Takeshi Shimamura,Samanthi A. Perera,Kevin P. Foley,Jim Sang,Scott J. Rodig,Takayo Inoue,Liang Chen,Danan Li,Julián Carretero,Yuchen Li,Papiya Sinha,Christopher D. Carey,Christa L. Borgman,John-Paul Jimenez,Matthew Meyerson,Weiwen Ying,James Barsoum,Kwok‐Kin Wong,Geoffrey I. Shapiro	131
11	Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profilingbreakdown → 2011 ·Journal of Clinical Oncology ·Nikhil Wagle,(unknown),Michael F. Berger,Matthew J. Davis,Allison M. Sawyer,Panisa Pochanard,Sarah M. Kehoe,Cory M. Johannessen,Laura E. MacConaill,William C. Hahn,Matthew Meyerson,Levi A. Garraway	732
12	High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing 2011 ·Cancer Discovery ·Nikhil Wagle,Michael F. Berger,Matthew J. Davis,Brendan Blumenstiel,Matthew DeFelice,Panisa Pochanard,Matthew D. Ducar,Paul Van Hummelen,Laura E. MacConaill,William C. Hahn,Matthew Meyerson,Stacey Gabriel,Levi A. Garraway	384
13	Amplification of CRKL Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non–Small Cell Lung Cancers 2011 ·Cancer Discovery ·Hiu Wing Cheung,Jinyan Du,Jesse S. Boehm,Frank He,Barbara A. Weir,Xiaoxing Wang,Mohit Butaney,Lecia V. Sequist,Biao Luo,Jeffrey A. Engelman,David E. Root,Matthew Meyerson,Todd R. Golub,Pasi A. Jänne,William C. Hahn	110
14	Recurrent BRAF mutations in Langerhans cell histiocytosisbreakdown → 2010 ·Blood ·Gayane Badalian‐Very,Jo‐Anne Vergilio,Barbara Degar,Laura E. MacConaill,Barbara Brandner,Monica L. Calicchio,Frank C. Kuo,Azra H. Ligon,Kristen E. Stevenson,Sarah M. Kehoe,Levi A. Garraway,William C. Hahn,Matthew Meyerson,Mark D. Fleming,Barrett J. Rollins	742
15	The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPbreakdown → 2008 ·Proceedings of the National Academy of Sciences ·Cai‐Hong Yun,Kristen E. Mengwasser,Angela V. Toms,Michele Sue‐Ann Woo,Heidi Greulich,Kwok‐Kin Wong,Matthew Meyerson,Michael J. Eck	1564
16	Transcriptional Profiling Identifies Cyclin D1 as a Critical Downstream Effector of Mutant Epidermal Growth Factor Receptor Signaling 2006 ·Cancer Research ·Susumu Kobayashi,Takeshi Shimamura,Stefano Monti,Ulrich Steidl,Christopher J. Hetherington,April M. Lowell,Todd R. Golub,Matthew Meyerson,Daniel G. Tenen,Geoffrey I. Shapiro,Balázs Halmos	98
17	Signal Transducer and Activator of Transcription 3 Is Required for the Oncogenic Effects of Non–Small-Cell Lung Cancer–Associated Mutations of the Epidermal Growth Factor Receptor 2006 ·Cancer Research ·James V. Alvarez,Heidi Greulich,William R. Sellers,Matthew Meyerson,David A. Frank	206
18	TMPRSS2:ERG Fusion-Associated Deletions Provide Insight into the Heterogeneity of Prostate Cancer 2006 ·Cancer Research ·Sven Perner,Francesca Demichelis,Rameen Beroukhim,Folke Schmidt,Juan Miguel Mosquera,Sunita R. Setlur,Joëlle Tchinda,Scott A. Tomlins,Matthias D. Hofer,Kenneth J. Pienta,Rainer Kuefer,Robert L. Vessella,Xiao Sun,Matthew Meyerson,Charles Lee,William R. Sellers,Arul M. Chinnaiyan,Mark A. Rubin	388
19	Homozygous Deletions and Chromosome Amplifications in Human Lung Carcinomas Revealed by Single Nucleotide Polymorphism Array Analysis 2005 ·Cancer Research ·Xiaojun Zhao,Barbara A. Weir,Thomas LaFramboise,Ming Gang Lin,Rameen Beroukhim,Levi A. Garraway,Javad Beheshti,Jeffrey C. Lee,Katsuhiko Naoki,William G. Richards,David J. Sugarbaker,Fei Chen,Mark A. Rubin,Pasi A. Jänne,Luc Girard,John D. Minna,David C. Christiani,Cheng Li,William R. Sellers,Matthew Meyerson	242
20	EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapybreakdown → 2004 ·Science ·J. Guillermo Paez,Pasi A. Jänne,Jeffrey C. Lee,Sean Tracy,Heidi Greulich,Stacey Gabriel,Paula Herman,Frederic J. Kaye,Neal I. Lindeman,Titus J. Boggon,Katsuhiko Naoki,Hidefumi Sasaki,Yoshitaka Fujii,Michael J. Eck,William R. Sellers,Bruce E. Johnson,Matthew Meyerson	7539

About Matthew Meyerson

Matthew Meyerson is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine, having authored 287 papers that have together received 58.9k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (68 papers), Lung Cancer Treatments and Mutations (64 papers) and RNA modifications and cancer (40 papers). The work is most often cited by research in Cancer Research (13.8k citations), Oncology (22.7k citations) and Pulmonary and Respiratory Medicine (19.9k citations). Matthew Meyerson has collaborated with scholars based in United States, Germany and Canada. Frequent co-authors include Gad Getz, Michael J. Eck, Pasi A. Jänne, Heidi Greulich, Bruce E. Johnson, Stacey Gabriel, Titus J. Boggon, William R. Sellers, Rameen Beroukhim and Craig H. Mermel. Their work appears in journals such as Nature, Science and New England Journal of Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact